17 results on '"Yang, J.C.H."'
Search Results
2. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
3. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
4. A Prospective Study for Circulating Exosome Integrins in Brain Metastases Identifies Exosomal β3 Integrin As a Novel Prognostic Biomarker after Palliative Whole-Brain Radiotherapy in Lung Cancer
5. Afatinib suivi d’osimertinib en vie réelle chez des patients avec CBNPC avancé EGFR muté : étude GioTag
6. Analyses des risques concurrents de progression systémique ou au niveau du système nerveux central chez des patients avec CBNPC EGFR muté ayant reçu de l’afatinib dans les études LUX-Lung 3, 6 et 7
7. Clinical Outcome and Toxicity Predictors of Thoracic Re-irradiation for Locoregionally Recurrent Lung Cancer
8. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
9. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
10. Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma
11. EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery
12. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies
13. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
14. 3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC
15. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
16. 213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors
17. 9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.